Clinical trials: Patients With Major Depressive Disorder
Myasthenia Gravis, Depression
Depressive Tendency and Counseling Outcomes in Thymoma-Associated MG
This study aimed to examine whether baseline depressive tendency independently predicts post-counseling clinical outcomes in patients with thymoma-associated MG.
- Conditions
- Myasthenia Gravis, Depression, Thymoma, Depression and Quality of Life
- Trial name
- NCT07649187
- Testing
- Psychological counseling intervention
- Where
- Taiwan
- Volunteers
- 19 people
- Sponsor
- Ming-Hsing Chang
Depression, Depressive Disorder
Study the Efficacy and Safety of the INtegral Cognitive REMediation Program (INCREM) for Depression
Feeling sad about negative or stressful events has nothing to do with the diagnosis of depression, as this is a very prevalent mental illness among the population with devastating consequences for the person suffering from it.
- Trial name
- INCREM (NCT06590025)
- Testing
- INtegral Cognitive REMediation program, Psychoeducation for depression
- Where
- Spain
- Volunteers
- 296 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Major Depressive Disorder, Psychedelic Experiences
Antidepressant Response of DMT Masked With Propofol
The aim of this study is to elucidate if the anti-depressive effect of N,N-dimethyltryptamine (DMT) is based on a biological mechanisms including neuroplasticity and anti-inflammatory effect or due to the subjective psychedelic…
- Trial name
- DMT4D (NCT06927076)
- Testing
- N,N-Dimethyltryptamine, Propofol, no sedation
- Where
- Switzerland
- Volunteers
- 112 people
- Sponsor
- University Hospital, Basel, Switzerland
Treatment-resistant Depression (TRD), Major Depression
Relationship of Peripheral Inflammatory and Neuroprotective Biomarkers With Response to Intermittent Theta Burst Stimulation in Treatment-Resistant Depression
Treatment-resistant depression (TRD) is a major clinical challenge affecting a substantial proportion of patients with major depressive disorder who do not adequately respond to conventional antidepressant treatments.
- Trial name
- TRD-BIOTMS (NCT07673913)
- Testing
- Intermittent Theta Burst Stimulation (iTBS)
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Gulhane Training and Research Hospital
Major Depressive Disorder
Early Improvement in Individual Symptoms and Response to Antidepressants in Patients With Major Depressive Disorder
Major depressive disorder (MDD) affects around 7% of the population yearly. Although effective treatments are available, only around half of all patients participating in clinical trials respond to 6 to 12 weeks of antidepressant…
- Trial name
- NCT02934035
- Testing
- Antidepressant
- Volunteers
- 10,000 people
- Sponsor
- University Medical Center Groningen
Major Depressive Disorder
Escitalopram in Adult Patients With Major Depressive Disorder
This is a short-term study to evaluate the efficacy, safety, and tolerability of escitalopram in adult patients (18 to 65 years of age) with moderate to severe depression.
- Trial name
- NCT00668525
- Testing
- Escitalopram
- Where
- 45 sites in United States
- Volunteers
- 877 people
- Sponsor
- Forest Laboratories
Major Depressive Disorder
Effect of Self-administered tDCS in Patients With MDD
In this randomized, single-blinded clinical trial, 58 patients with major depressive disorder were assigned to active and sham tDCS stimulation groups in a 1:1 ratio, and treatment responses were evaluated biweekly over six weeks.
- Trial name
- NCT04543123
- Testing
- tDCS treatment, Antidepressant Drug(escitalopram)
- Where
- South Korea
- Volunteers
- 58 people
- Sponsor
- Jeong-Ho Chae
Mental Health Issue
Effects of Cognitive-Oriented Intervention on Major Depressive Disorder
The specific aims of the study were to explore the effects of the cognitive-oriented intervention program for promoting social support on perceived social supports, depression symptoms, and stress-coping strategies for patients…
- Trial name
- NCT05296174
- Testing
- cognitive-oriented intervention program, health education activities program
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Mackay Medical College
Adrenal Gland Hyperfunction, Cardiovascular Disease
Heart Disease Risk Factors in Major Depression
A series of studies in patients with major depression have consistently demonstrated a doubling of the mortality rate at any age, independent of suicide.
- Conditions
- Adrenal Gland Hyperfunction, Cardiovascular Disease, Involutional Depression
- Trial name
- NCT00001969
- Where
- United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Major Depressive Disorder
Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression
The study will consist of a 24-week-long trial examining outcomes in patients with Major Depressive Disorder and suicidal ideation who will receive intravenous (IV) ketamine and intranasal (IN) esketamine, compared to a large…
- Trial name
- NCT05450432
- Testing
- Ketamine, Esketamine
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression
The purpose of this study is to determine whether GLYX-13 reduces depression score in patients with treatment-resistant depression.
- Trial name
- NCT01234558
- Testing
- GLYX-13
- Where
- United States
- Volunteers
- 115 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Migraine, Major Depressive Disorder
A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder
The primary objective is to evaluate the efficacy of monthly 225 mg sc fremanezumab in adult participants with migraine and major depressive disorder (MDD) The secondary objectives are to evaluate the efficacy of monthly 225 mg…
- Trial name
- NCT04041284
- Testing
- Fremanezumab
- Where
- 64 sites in United States, Czechia and 11 more
- Volunteers
- 353 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Mild Cognitive Impairment (MCI), Depression
Brain Aging and Treatment Response in Geriatric Depression
The proposed project will evaluate the role of neuroimaging biomarkers of brain aging (i.e., neurodegenerative and vascular brain changes) and mild cognitive impairment in the patterns of treatment response to memantine combined…
- Trial name
- NCT01902004
- Testing
- Escitalopram, Memantine
- Where
- United States
- Volunteers
- 115 people
- Sponsor
- University of California, Los Angeles
Bipolar Disorder, Major Depressive Disorder
Pregnenolone Trial for Depression in Bipolar Disorders or Recurrent Major Depressive Disorder With Substance Abuse
The purpose of this research is to determine if pregnenolone supplement is associated with a reduction in substance use and craving in patients with recurrent major depressive disorder or bipolar disorder and substance…
- Conditions
- Bipolar Disorder, Major Depressive Disorder, Substance Abuse
- Trial name
- NCT00223197
- Testing
- Pregnenolone
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- University of Texas Southwestern Medical Center
Major Depressive Disorder
Open-Label Treatment With Duloxetine Hydrochloride Once-Daily Dosing for Evaluation of Stabilization Dose in Patients With Major Depression
The purposes of this study are to determine: The safety of duloxetine and any side effects that might be associated with it. Whether duloxetine can help patients with major depression.
- Trial name
- NCT00042562
- Testing
- duloxetine
- Where
- 23 sites in United States
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
Electrophysiologic Parameters and Biomarkers Predicting Treatment Response in Patients With Major Depressive Disorder
To explore electrophysiologic parameters and biomarkers predicting treatment response of patients with major depressive disorder To explore electrophysiologic parameters and biomarkers predicting suicide risk of patients with…
- Trial name
- NCT01997580
- Testing
- escitalopram
- Where
- South Korea
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Seoul National University Bundang Hospital
Major Depressive Disorder(MDD)
Efficacy of Clinical Application of Transcranial Low Intensity Focused Ultrasonic Stimulation for Patients With Major Deperessive Disorder - Exploratory Clinical Trial
The non-invasive type ultrasonography system is applied to patients with major depressive disorder to evaluate their effectiveness and safety.
- Trial name
- NCT04405791
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Gangnam Severance Hospital
Depressive Disorder, Major
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
The purpose of this study is to know how well seltorexant works, and also to evaluate safety and maintenance effect of seltorexant compared with placebo as an adjunctive therapy to an antidepressant in improving depressive…
- Trial name
- NCT06559306
- Testing
- Seltorexant, Selective Serotonin Reuptake Inhibitor (SSRI)/Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
- Where
- 205 sites in United States, Argentina and 14 more
- Volunteers
- 752 people
- Sponsor
- Janssen Research & Development, LLC
Depressive Disorder, Major
CONCERTA® (Methylphenidate Hydrochloride) as add-on Therapy in the Treatment of Adult Major Depressive Disorder.
The purpose of this study is to evaluate the effects of the addition of CONCERTA® (methylphenidate hydrochloride, a central nervous system (CNS) stimulant) or placebo in adult outpatients with Major Depressive Disorder who are…
- Trial name
- NCT00246233
- Testing
- methylphenidate
- Volunteers
- 145 people
- Sponsor
- Janssen-Ortho Inc., Canada
Major Depressive Disorder (MDD), Major Depressive Disorder With Psychotic Features
Study of Lurasidone as Adjunctive Treatment in Patients With Major Depressive Disorder With Inadequate Response to Antidepressant Monotherapy
This Phase 3, multicenter, randomized, double-blind, placebo-controlled clinical trial is designed to evaluate the efficacy and safety of lurasidone as adjunctive therapy in adult patients with major depressive disorder (MDD) who…
- Trial name
- NCT07781293
- Testing
- Lurasidone, Background Antidepressant Therapy
- Volunteers
- 364 people
- Sponsor
- Bukwang Pharmaceutical